Related Experiment Video

Updated: Aug 30, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Management of hepatitis B and C in HIV co-infected patients

Jürgen Kurt Rockstroh1

  • 1University of Bonn, Bonn, Germany. rockstroh@uni-bonn.de

Journal of Acquired Immune Deficiency Syndromes (1999)
|October 18, 2003
PubMed

Insights

Managing co-infections of human immunodeficiency virus (HIV) with hepatitis B (HBV) or hepatitis C (HCV) is complex. These co-infections accelerate liver disease, increasing morbidity and mortality, necessitating tailored treatment strategies.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Virology

Background:

  • Co-infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) in human immunodeficiency virus (HIV)-infected patients presents significant clinical challenges.
  • HIV co-infection accelerates liver disease progression, increasing the risk of cirrhosis and mortality from chronic HBV and HCV infections.
  • While less than 10% of HIV patients have chronic HBV, it's characterized by high replication and cirrhosis risk. Approximately 30% of HIV patients in Europe are co-infected with HCV.

Purpose of the Study:

  • To highlight the increasing morbidity and mortality associated with HBV/HCV co-infections in HIV patients.
  • To underscore the challenges in managing these complex co-infections.
  • To emphasize the need for developing specific treatment strategies for HBV and HCV in HIV co-infected individuals.

Main Methods:

  • Review of current clinical management issues and treatment options for HIV/HBV and HIV/HCV co-infections.
  • Analysis of disease progression and outcomes in co-infected patients compared to single infections.
  • Evaluation of existing and emerging therapeutic interventions, including lamivudine, adefovir, tenofovir, pegylated interferon, and ribavirin.

Main Results:

  • Hepatitis B in HIV co-infected patients shows high HBV replication and cirrhosis risk; lamivudine is a primary treatment, with adefovir/tenofovir showing efficacy in 3TC-resistant cases.
  • HIV accelerates HCV liver disease, with 15-25% of co-infected patients developing cirrhosis within 10-15 years, significantly higher than in HIV-negative patients.
  • Pegylated interferon and ribavirin offer promising treatment for HIV/HCV co-infection, achieving early virological response rates around 50%.

Conclusions:

  • The management of HIV/HBV and HIV/HCV co-infections is a critical clinical issue due to accelerated liver disease and increased mortality.
  • Effective treatment strategies are essential for improving outcomes in patients with these co-infections.
  • Further research and clinical guidelines are needed to optimize the care of HIV-infected individuals with HBV or HCV.

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
Standard Precaution01:26

Standard Precaution

Standard precautions are the minimum infection control safeguards used while caring for all patients, irrespective of their disease condition. They help prevent the spread of common infectious microorganisms to healthcare workers, patients, and visitors in all healthcare settings.
Hand hygiene is the most crucial means to prevent the transmission of disease. Employers are legally required to provide their workers with personal protective equipment (PPE) to minimize exposure or contact with...